Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study "GeCCO"
Terminated
Phase N/A Results N/ASummary of Purpose
The primary objective of this trial is to demonstrate the non-inferiority of clopidogrel compared to prasugrel over 6 months in cardiovascular disease patients when the clopidogrel cohort is limited to the estimated 70% of the population that are CYP2C19 extensive metabolizers. This protocol will examine the comparative... Trial Stopped: Administrative reasons
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 29 May 2012.
1 Oct 2009 | 14 Oct 2009 | 1 May 2012 | 1 May 2012 | 1 May 2012 | Unavailable |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Basics
Conditions
Sponsors
Trial Design
- Observation: Cohort
- Perspective: Prospective
- Sampling: Non-Probability Sample
Contacts
Not available
View Trial Locations
Recruitment
- Enrollment: 4,471
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 1 location, 1 country
Principal Investigator
- Eric J Stanek, Pharm.D.
Medco Health Solutions, Inc.